Ray Dalio's ACAD Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 138,179 shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $3.69 M, representing 0.01% of the portfolio. First purchased in 2022-Q1, this short-term holding has been held for 5 quarters.
Based on 13F filings, Ray Dalio has maintained this position in ACAD for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 163,245 shares. Largest reduction occurred in Q4 2025, reducing 25,066 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2022 | +8,989 | New Buy | 8,989 | $24.25 |
| Q2 2022 | +1,929 | Add 21.46% | 10,918 | $14.11 |
| Q3 2022 | -10,918 | Sold Out | 0 | $0.00 |
| Q3 2025 | +163,245 | New Buy | 163,245 | $21.34 |
| Q4 2025 | -25,066 | Reduce 15.35% | 138,179 | $26.71 |
Ray Dalio's ACADIA Pharmaceuticals Investment FAQs
Ray Dalio first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q1 2022, acquiring 8,989 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held ACADIA Pharmaceuticals Inc. (ACAD) for 5 quarters since Q1 2022.
Ray Dalio's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q3 2025, adding 163,245 shares worth $3.48 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 138,179 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $3.69 M.
As of the Q4 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 163,245 shares, as reported at the end of Q3 2025.